4D MOLECULAR THERAPEUTICS, INC. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT4d Molecular • February 29th, 2024 • 4D Molecular Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledFebruary 29th, 2024 Company Industry JurisdictionThis Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Robert Young Kim (“Executive”) and 4D Molecular Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).